Yes Matador Termination of proposed acquisition of Yooya by Regent Pacific is so difficult to understand.
Regent Pacific have today reported that discussions in respect of the possible acquisition have terminated, effective as of 17 July 2019.
From the regent RNS
The Board would like to inform Shareholders that discussions in respect of such possible acquisition have now terminated, effective as of 17 July 2019, on account of all the relevant parties being unable to reach agreement on the key terms of the acquisition.
Cannacord led the recent fund raise. The only significant private company fundraise they’ve done this year. Believed to be working on a £400 million listing according to the Times.
Cannacord have led virtually all the significant cannabis raises globally for a number of years.
31 countries in Europe have legalised medical cannabis.Emmac quickly developing business that controls the cultivation, manufacturing, R&D, importing, distribution and branding of its products.
Acquired Swiss company Blossom that makes CBD oils, balms and hemp teas. This is generating revenue now.
Portugal will be the cultivation & production hub and has bought a licensed firm in order to do this.
Malta have the lowest corporation tax in Europe so was an ideal location for its distribution base for moving product within and out of Europe & have bought a licensed company to do this.
EMMAC bought Medalchemy, a pharma ingredients manufacturer in Spain who have a highly desired and ultra difficult to obtain, medical cannabis import license.
Bought outright Rokshaw Limited is a leading UK MHRA approved Specials manufacturer who produce a wide range of Specials bespoke to patient requirements in an EU GMP environment to ensure that patients across the UK receive the highest quality products. Rokshaw has already manufactured more than 6,000 formulations for over 2,000 pharmacies and hospitals across the UK. They are immediately revenue generating.
Formed a JV with Farmalabor in Italy, one of Italy's most active licensed importers and distributors of medical cannabis. has already submitted applications for licenses to import, store, manufacture and distribute medical cannabis products in Italy, which is the second-largest medical cannabis market in Europe.
Bought French company Greenleaf. The provides an established e-commerce and retail distribution model in France as well as a proven portfolio of hemp-based wellness products, under the Hello Joya brand. Immediately revenue generating.
Emmac has entered the German medical cannabis market through the incorporation of About Nature Health GmbH a wholly owned subsidiary of the Company, which will lead the marketing and licensing process for EMMAC in Germany. Going to be working in conjunction with Medalchemy (see above for details). They have into a supply agreement in place with CC Pharma, a leading importer and distributor of EU-pharmaceuticals for Germany.
Terra Verde is largest acquisition to date and completes the full integration of EMMAC’s supply chain, which to date comprises GACP cultivation, extraction and manufacturing in accordance with EU Good Manufacturing Practices (GMP), and licensed distribution channels for medical cannabis in the UK, Germany and Italy.
Emmac has appointed VCCP to be their lead creative and strategic agency.
July 16, 2019 02:00 AM Eastern Daylight Time
LONDON--(BUSINESS WIRE)--EMMAC Life Sciences Ltd (“EMMAC” or the “Company”), the leading European independent medical cannabis and wellness company, is pleased to announce that it has acquired 100% of Terra Verde, LDA (“Terra Verde”), a Portuguese genetics and cultivation company. This acquisition establishes EMMAC as the largest vertically integrated cannabis company in Europe, with operations in eight territories and licensed distribution channels for medical cannabis in Europe’s largest medical cannabis markets, namely Germany, Italy and the UK.
The acquisition of Terra Verde is EMMAC’s largest acquisition to date and completes the full integration of EMMAC’s supply chain, which to date comprises GACP cultivation, extraction and manufacturing in accordance with EU Good Manufacturing Practices (GMP), and licensed distribution channels for medical cannabis in the UK, Germany and Italy.
Terra Verde was founded by David Yarkoni, a world-renowned breeder and geneticist who has pioneered plant-based research and production for more than 30 years. In 2014, Terra Verde acquired Portugal’s first, and Europe’s second, active cultivation license. This license allows for eight hectares of greenhouse and outdoors cannabis cultivation. Its current crop of high-grade medical cannabis, which is grown in accordance with EU Good Agricultural and Collection Practices (GACP), is due for harvest in 30 days.
Following completion of the acquisition, EMMAC will begin to invest significantly in Terra Verde’s facilities, including the construction of a GMP-certified facility for storage, processing and manufacturing at the Portuguese site that will serve both the domestic and the international markets.
Antonio Costanzo, CEO of EMMAC, commented: “We are delighted to have acquired Terra Verde, a unique asset in the European medical cannabis space that was founded by one of the most well-regarded plant-based researchers. With the acquisition of Terra Verde, EMMAC is now the largest vertically integrated European cannabis company and a leader in the industry. We are delighted to welcome David and his team in Portugal to EMMAC.
“With this milestone firmly achieved, EMMAC’s focus now is to extend the pan-European reach of our medical and wellness portfolio. We will continue to partner with the best organisations and businesses in the sector and support cutting-edge scientific research to further develop the medical cannabis sector.”
David Yarkoni, Founder of Terra Verde, commented: “Speaking on behalf Terra Verde’s team and shareholders, I am delighted to partner with EMMAC to maximise Terra Verde’s potential to be the best cultivation facility in Europe. We had been approached by multiple organisations, however we decided to partner with EMMAC due to its distribution network, world-class team and scientific approach. EMMAC has built the perfect platform to become the European leader. We look forward to working